Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082725
PUBLISHER: DelveInsight | PRODUCT CODE: 2082725
Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2036
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Antiphospholipid Syndrome (APS) Insights and Trends
- According to DelveInsight's analysis, the total prevalent cases of APS were ~ 310,800 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- APS is more prevalent in Asian countries such as Japan due to higher detection rates, increased awareness of autoimmune disorders, genetic predisposition, and a growing burden of associated conditions such as Systemic Lupus Erythematosus.
- According to a study by Dabitt et al. (2021), the prevalence of antiphospholipid antibodies in patients with obstetric morbidity was 6-9%, while in arterial events and venous thromboembolism is 9-10%.
- Antiphospholipid syndrome affects 3 to 5 times as many women as men. Although there's no cure for APS, the risk of developing blood clots can be greatly reduced if it's correctly diagnosed.
- Females face a higher lifetime risk of developing APS and experience a greater disease burden compared to males. This disparity is largely attributed to the higher prevalence of autoimmune conditions in women, hormonal influences, and reproductive factors, as women are more likely to experience pregnancy-related complications such as recurrent miscarriages and obstetric morbidity associated with APS.
- Rising awareness, improved diagnostic capabilities, increasing prevalence of autoimmune disorders such as Systemic Lupus Erythematosus, and persistent thrombotic risk factors are expected to sustain the global APS burden over the next decade. Strengthening early diagnosis, optimizing long-term anticoagulation strategies, and advancing targeted therapies will remain key determinants of future trends.
Antiphospholipid Syndrome (APS) Epidemiology Forecast in 7MM
- 2025 Prevalent Cases of APS: ~ 310,800
- APS Growth Rate (2026-2036): ~0.7%CAGR
DelveInsight's 'Antiphospholipid Syndrome (APS) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the APS, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Antiphospholipid Syndrome (APS) Understanding and Diagnosis Algorithm
APS Overview
APS is an autoimmune disorder in which abnormal antibodies increase the risk of blood clots in arteries and veins. It can lead to complications such as deep vein thrombosis, stroke, and recurrent pregnancy loss. APS is caused by immune system dysfunction and may occur alone or with other autoimmune diseases. Diagnosis is based on blood tests for specific antibodies, and treatment mainly involves long-term anticoagulation to prevent clot formation.
APS Diagnosis
APS is diagnosed based on clinical history and blood tests, often suspected in patients with unexplained blood clots or recurrent pregnancy loss. Diagnosis is confirmed by detecting antiphospholipid antibodies such as lupus anticoagulant, anti-cardiolipin, and anti-B2 glycoprotein I on two occasions at least 12 weeks apart. Imaging tests may be used to identify associated thrombosis.
Antiphospholipid Syndrome (APS) Epidemiology
Key Findings from APS Epidemiological Analysis and Forecast
- According to DelveInsight's estimates, the total prevalent cases of APS in the 7MM were approximately 310,800 in 2025.
- Among the EU4, Germany accounted for the highest number of prevalent cases of APS, followed by France, whereas Italy accounted for the lowest number of cases in 2025.
- The observed female predominance and earlier onset of APS highlight the importance of early screening, timely diagnosis, and tailored management strategies, particularly in women of reproductive age, to reduce thrombotic risk and improve pregnancy outcomes.
- The prevalence of APS was 51.18% in the US population. Males had a lower prevalence of APS than females.
Scope of the Report:
- The report covers a segment of an executive summary, a descriptive overview of APS, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Antiphospholipid Syndrome (APS) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of APS? What will be the growth opportunities across the 7MM concerning the patient population with APS?
- What is the historical and forecasted APSpatient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI0484
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of APS
4. Epidemiology Forecast Methodology of APS
5. APS Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background and Overview of APS
- 6.1. Introduction
- 6.2. Signs and Symptoms
- 6.3. Causes
- 6.4. Risk Factors Associated With APS
- 6.5. Pathophysiology
- 6.6. Diagnosis
- 6.6.1. Differential Diagnosis
- 6.6.2. Diagnosis Algorithm
- 6.6.3. Diagnosis Guidelines
7. Epidemiology and Patient Population of APS
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Prevalent Cases of APS in the 7MM
- 7.4. The United States
- 7.4.1. Total Prevalent Cases of Antiphospholipid Syndrome (APS) in US
- 7.4.2. Diagnosed Prevalent Cases of Antiphospholipid Syndrome (APS) in US
- 7.4.3. Gender-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (APS) in US
- 7.4.4. Age-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (APS) in US
- 7.4.5. Clinical manifestations of Antiphospholipid Syndrome (APS) in US
- 7.4.6. Treatable Cases of Antiphospholipid Syndrome (APS) in US
- 7.5. EU4 and the UK
- 7.5.1. Total Prevalent Cases of Antiphospholipid Syndrome (APS) in EU4 and the UK
- 7.5.2. Diagnosed Prevalent Cases of Antiphospholipid Syndrome (APS) in EU4 and the UK
- 7.5.3. Gender-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (APS) in EU4 and the UK
- 7.5.4. Age-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (APS) in EU4 and the UK
- 7.5.5. Clinical manifestations of Antiphospholipid Syndrome (APS) in EU4 and the UK
- 7.5.6. Treatable Cases of Antiphospholipid Syndrome (APS) in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Prevalent Cases of Antiphospholipid Syndrome (APS) in Japan
- 7.6.2. Diagnosed Prevalent Cases of Antiphospholipid Syndrome (APS) in Japan
- 7.6.3. Gender-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (APS) in Japan
- 7.6.4. Age-Specific Diagnosed Prevalent Cases of Iron Deficiency Anemia (APS) in Japan
- 7.6.5. Clinical manifestations of Antiphospholipid Syndrome (APS) in Japan
- 7.6.6. Treatable Cases of Antiphospholipid Syndrome (APS) in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Product Code: DIEI0484
List of Tables
- Table 1: Prevalence of Antiphospholipid Antibodies in Different Clinical Conditions
- Table 2: Key Concepts for Clinicians Evaluating the Results of Antiphospholipid Antibody Testing*
- Table 3: SSC-ISTH Guidelines for Antiphospholipid Antibody Detection
- Table 4: Prevalent Cases of Antiphospholipid Syndrome in the 7MM (2022-2036)
- Table 5: Diagnosed Cases of Antiphospholipid Syndrome in the 7MM (2022-2036)
- Table 6: Diagnosed Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Table 7: Age-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Table 8: Gender-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Table 9: Type-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Table 10: Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Table 11: Treated Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Table 12: Diagnosed Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Table 13: Age-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Table 14: Gender-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Table 15: Type-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Table 16: Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Table 17: Treated Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Table 18: Diagnosed Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Table 19: Age-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Table 20: Gender-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Table 21: Type-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Table 22: Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Table 23: Treated Cases of Antiphospholipid Syndrome in Japan (2022-2036)
List of Figures
- Figure 1: Venn Diagram of the Clinical Presentation of APS
- Figure 2: Symptoms of APS
- Figure 3: Some of the Risk Factors of APS
- Figure 4: Other Manifestations Associated With APS
- Figure 5: Proposed Structures of the Open and Closed Forms of B2GPI
- Figure 6: Pathogenic Mechanisms of APS
- Figure 7: Diagnosis of APS
- Figure 8: Prevalent Cases of Antiphospholipid Syndrome in the 7MM (2022-2036)
- Figure 9: Diagnosed Cases of Antiphospholipid Syndrome in the 7MM (2022-2036)
- Figure 10: Diagnosed Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Figure 11: Age-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Figure 12: Gender-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Figure 13: Type-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Figure 14: Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Figure 15: Treated Cases of Antiphospholipid Syndrome in the United States (2022-2036)
- Figure 16: Diagnosed Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Figure 17: Age-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Figure 18: Gender-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Figure 19: Type-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Figure 20: Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Figure 21: Treated Cases of Antiphospholipid Syndrome in EU4 and the UK (2022-2036)
- Figure 22: Diagnosed Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Figure 23: Age-specific Cases Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Figure 24: Gender-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Figure 25: Type-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Figure 26: Clinical Manifestation-specific Cases of Antiphospholipid Syndrome in Japan (2022-2036)
- Figure 27: Treated Cases of Antiphospholipid Syndrome in Japan (2022-2036)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.